NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free APLT Stock Alerts $4.46 -0.18 (-3.88%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$4.40▼$5.1850-Day Range$4.23▼$6.9352-Week Range$1.18▼$9.39Volume804,669 shsAverage Volume1.72 million shsMarket Capitalization$509.64 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Applied Therapeutics alerts: Email Address Applied Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.6% Upside$11.00 Price TargetShort InterestHealthy3.91% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.17Based on 9 Articles This WeekInsider TradingSelling Shares$2.47 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.80 out of 5 starsMedical Sector36th out of 928 stocksPharmaceutical Preparations Industry15th out of 431 stocks 4.5 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Applied Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.91% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Applied Therapeutics has recently decreased by 5.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 2.3 News and Social Media Coverage News SentimentApplied Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Applied Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for APLT on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,469,181.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Applied Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Applied Therapeutics Stock (NASDAQ:APLT)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More APLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLT Stock News HeadlinesMay 10, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...May 9, 2024 | investorplace.comAPLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comApplied Therapeutics GAAP EPS of -$0.67 misses by $0.51May 9, 2024 | globenewswire.comApplied Therapeutics Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comApplied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 15, 2024 | globenewswire.comApplied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerApril 14, 2024 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)April 6, 2024 | investing.comApplied Therapeutics reveals Phase 3 data on heart drugApril 4, 2024 | finance.yahoo.comApplied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)April 1, 2024 | benzinga.comFDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare DiseaseApril 1, 2024 | benzinga.comWhy Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | markets.businessinsider.comApplied Therapeutics Says FDA Extends Review Period Of NDA For GovorestatMarch 28, 2024 | finance.yahoo.comUPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | reuters.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | globenewswire.comApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaMarch 20, 2024 | investing.comApplied therapeutics CCO sells shares worth over $263kMarch 20, 2024 | investing.comApplied therapeutics CFO sells shares worth over $150kMarch 8, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical ProgressMarch 6, 2024 | globenewswire.comApplied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market ProspectsMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial PositionFebruary 28, 2024 | marketwatch.comApplied Therapeutics Shares Surge on FDA Review, $100 Million Funding RoundFebruary 28, 2024 | markets.businessinsider.comApplied Therapeutics Rallies After Announcing Private Placement Of SharesFebruary 28, 2024 | msn.comFDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic DisorderSee More Headlines Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees25Year Founded2017Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+137.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net MarginsN/A Pretax Margin-1,198.47% Return on Equity-1,497.37% Return on Assets-176.54% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$-477,000.00 Price / Sales-1,111.53 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-23.20Miscellaneous Outstanding Shares114,267,000Free Float104,440,000Market Cap$530.20 million OptionableOptionable Beta1.91 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Shoshana Shendelman Ph.D. (Age 45)Chair of the Board of Directors, Founder, President, CEO & Secretary Comp: $813.47kMr. Les D. Funtleyder (Age 53)CFO, Principal Financial Officer & Independent Director Comp: $40kDr. Riccardo Perfetti M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $858kMr. Adam Hansard (Age 47)Chief Commercial Officer Comp: $742.66kMr. Constantine Chinoporos (Age 58)COO & Chief Business Officer Ms. Catherine Thorpe (Age 60)Chief Accounting Officer More ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVY-mAbs TherapeuticsNASDAQ:YMABVerve TherapeuticsNASDAQ:VERVAerovate TherapeuticsNASDAQ:AVTEAstria TherapeuticsNASDAQ:ATXSView All CompetitorsInsiders & InstitutionsAltitude Crest Partners Inc.Bought 259,700 shares on 5/15/2024Ownership: 0.227%Propel Bio Management LLCBought 736,924 shares on 5/14/2024Ownership: 5.349%StemPoint Capital LPBought 1,109,864 shares on 5/14/2024Ownership: 1.765%EntryPoint Capital LLCBought 40,070 shares on 5/14/2024Ownership: 0.035%Richmond Brothers Inc.Sold 61,827 shares on 5/10/2024Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions APLT Stock Analysis - Frequently Asked Questions Should I buy or sell Applied Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks. What is Applied Therapeutics' stock price target for 2024? 5 brokerages have issued twelve-month target prices for Applied Therapeutics' shares. Their APLT share price targets range from $7.00 to $13.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 146.6% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts. How have APLT shares performed in 2024? Applied Therapeutics' stock was trading at $3.35 at the start of the year. Since then, APLT stock has increased by 33.1% and is now trading at $4.46. View the best growth stocks for 2024 here. When is Applied Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our APLT earnings forecast. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) issued its earnings results on Wednesday, March, 6th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.18. The business earned ($0.67) million during the quarter. What ETF holds Applied Therapeutics' stock? Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 13.00% of its portfolio. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX). When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Applied Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Propel Bio Management LLC (5.35%), Vanguard Group Inc. (2.64%), StemPoint Capital LP (1.77%), Altitude Crest Partners Inc. (0.23%), Richmond Brothers Inc. (0.05%) and EntryPoint Capital LLC (0.04%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APLT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
